PJ14

POPULATION PHARMACOKINETIC MODELING OF FLUOXETINE IN RATS TO DETERMINATE DIFFERENCES AMONG INDIVIDUALS CLASSIFIED ACCORDING TO THEIR PLASMA SEX HORMONES

PJ15

POPULATION PHARMACOKINETIC MODELING IN RATS OF ISOQUERCETIN PRESENT IN Passiflora ligularis EXTRACT - LOADED SELF-EMULSIFYING SYSTEM

PJ16

PHARMACOGENETIC AND PHARMACOKINETIC STUDY OF CARIBBEAN HISPANICS TREATED WITH BUPRENORPHINE

PJ17

PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING APPLIED TO CHILD SAFETY AND RISK ASSESSMENTS: SODIUM VALPROATE

RP13

PHYSIOLOGICALLY BASED BIOPHARMACEUTICS MODELING TO PREDICT OMEPRAZOLE BIOAVAILABILITY FROM ENTERIC-COATED MICROGRANULES 

RP14

APPLIED CONCEPTS IN PBPK MODELING IN PhysPK: DISSOLUTION, ABSORPTION, INTESTINAL TRANSIT AND PH EFFECT

RP15

POPULATION PHARMACOKINETIC MODEL OF METHOTREXATE IN BRAZILIAN PEDIATRIC PATIENTS WITH ACUTE LIMPHOBLASTIC LEUKEMIA

RP16

POPULATION PHARMACOKINETIC MODEL OF CIPROFLOXACIN LUNG AND EPITHELIAL LINING FLUID DISTRIBUTION IN DIFFERENT STAGES OF Pseudomonas aeruginosa LUNG INFECTION IN RODENTS

RP17

A JOINT PARENT-METABOLITE MODEL TO CHARACTERIZE SEX-RELATED DIFFERENCES OBSERVED IN LEVODOPA AND 3-O-METHYLDOPA PHARMACOKINETICS IN HEALTHY SUBJECTS

TC12

DESIGN OF A STRATEGY TO OPTIMIZE ANTIBIOTIC TREATMENT WITH PIPERACILLIN/TAZOBACTAM IN NEONATES WITH SEVERE INFECTIONS USING A POPULATION-BASED APPROACH

TC13

COMPARATIVE ANALYSIS OF BAYESIAN CLINICAL DECISION SUPPORT SOFTWARE OF VANCOMYCIN DOSING (DoseMeRx®) VERSUS CLINICIAN GUIDED VANCOMYCIN DOSING IN AN INPATIENT POPULATION

TC14

DOWN-REGULATION OF TESTOSTERONE IN PIGS AFTER SUSTAINED-RELEASE SUBCUTANEOUS ADMINISTRATION OF A SINGLE DOSE OF 4.7 MG OF DESLORELIN

PJ18

A SEMI-MECHANISTIC PBPK MODEL FOR VORICONAZOLE BRAIN DISTRIBUTION IN RATS  AS A TOOL TO PREDICT BRAIN LEVELS EXPOSURE IN HUMANS WITH MENINGITES

PJ19

PHARMACOMETRICS STUDIES OF THERAPEUTIC PEPTIDES CIGB-500, CIGB-300 AND CIGB-814

PJ2

POSOLOGICAL OPTIMIZATION OF USTEKINUMAB AND SECUKINUMAB IN PSORIASIS

PJ3

INTEGRATING STATISTICAL AND MECHANISTIC MODELING TO EXPLAIN INTRA-INDIVIDUAL VARIABILITY IN DRUG BIOEQUIVALENCE STUDIES: A PATH TO VIRTUAL BIOEQUIVALENCE

RP18

PK/PD MODELING OF WARFARIN IN A BRAZILIAN POPULATION: FROM NONMEM TO MONOLIX

RP19

POPULATION PHARMACOKINETIC OF 1B8 MONOCLONAL ANTIBODY IN PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA

RP7

PK AND PD CHARACTERIZATION OF WARFARIN RESPONSE IN PUERTO RICAN PATIENTS BASED ON INDIVIDUAL GENOTYPES

RP20

DEVELOPMENT AND VERIFICATION OF PBPK MODEL FOR VENLAFAXINE

RP21

PHARMACOKINETIC MODELING BASED ON PHYSIOLOGY (PBPK) OF PIPERACILLIN IN NAÏVE RATS

TC2

MODEL-INFORMED PRECISION DOSING OF LEVETIRACETAM IN PEDIATRICS POPULATION 

TC3

POPULATION PHARMACOKINETICS/PHARMACODYNAMICS MODELING OF CLOZAPINE-LOADED NANOCAPSULES IN RATS

TC4

DEVELOPMENT OF A PHARMACOKINETIC MODEL BASED ON PHYSIOLOGY (PBPK) TO EVALUATE THE DRUG PHARMACOKINETIC INTERACTION BETWEEN BUPROPIONA AND RIFAMPICIN IN PATIENTS WITH TUBERCULOSIS

PJ4

PHARMACOKINETIC-PHARMACODYNAMIC MODEL OF FUNGISTATIC EFFECT OF AMPHOTERICIN B AGAINST Candida albicans

PJ5

POPULATION PHARMACOKINETIC MODELING OF AMPHOTERICIN B IN PEDIATRICS

PJ6

PHYSIOLOGY-BASED PHARMACOKINETIC (PBPK) MODELING OF METHYLPHENIDATE FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER IN ADULTS

PJ7

PHARMACOKINETICS/PHARMACODYNAMICS MODELING OF THE ARTESUNATE E MEFLOQUINE ASSOCIATION

RP3

PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODEL OF CARVEDILOL IN PATIENTS BEFORE AND AFTER ROUX-EN-Y GASTRIC BYPASS SURGERY

RP4

PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING OF HIDROXICHLOROQUINE ENANTIOMERS IN HEALTHY VOLUNTEERS

RP5

PHARMACOLOGICAL INTERACTIONS OF MONOTERPENES AND IN VIVO EVALUATION OF THEIR NEMATODICIDAL ACTIVITY

RP6

POPULATION PHARMACOKINETIC MODELLING OF TOBRAMYCIN LUNG AND EPITHELIAL LINING FLUID ALTERED DISPOSITION DUE TO BIOFILM-FORMING Pseudomonas aeruginosa INFECTION

RP22

DEVELOPMENT OF R-KETAMINE PHYSIOLOGICALLY‐BASED PHARMACOKINETICS (PBPK) MODEL

TC6

POPULATION PK/PD STUDY OF QUININE-LOADED NANOCAPSULES WITH DIFFERENT SURFACE CHARGES

TC5

CEFTAROLINE POPULATION PHARMACOKINETIC MODEL CHARACTERIZING DISTRIBUTION TO MUSCLE AND SUBCUTANEOUS TISSUES OF HEALTHY VOLUNTEERS AND CEREBROSPINAL FLUID OF NEUROSURGICAL PATIENTS

PJ8

IMPLEMENTATION OF A PILOT THERAPEUTIC DRUG MONITORING PROGRAM FOR ANTIBIOTICS IN PEDIATRIC PATIENTS

PJ9

VALIDATION METHOD ANALYTICAL BY UPLC-MSMS FOR SIMULTANEOUS QUANTIFICATION OF LAMOTRIGINE, CARBAMAZEPINE, TOPIRAMATE, LEVETIRACETAM

PJ13

PHARMACOKINETIC PROFILE OF DEXAMETHASONE IN COVID-19 PATIENTS

RP2

ASSESSING IVIVC/R OF LAMOTRIGINE IR USING PBBM APPROACH

RP8

PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODEL TO ASSESS POTENCIAL DISEASE-DRUG-DRUG INTERACTIONS WITH REMDESIVIR

RP9

POPULATION PHARMACOKINETICS MODELING OF NANOENCAPSULATED MELOXICAM IN FEMALE DOGS

TC7

DESCRIPTIVE POPULATION MODELING OF MATRIX EFFECTS OF AN EXTRACT OF CALYCES FROM Physalis Peruviana L. ON RUTIN PHARMACOKINETICS IN WISTAR RATS

TC8

MODEL-BASED BIOEQUIVALENCE ANALYSIS TO ASSESS AND PREDICT THE RELATIVE BIOAVAILABILITY OF VALPROIC ACID FORMULATIONS

TC9

PERFORMANCE EVALUATION OF A PRECISION DOSING SERVICE FOR VANCOMYCIN IN A TERTIARY LEVEL PEDIATRIC HOSPITAL